psychedelic drugs
Coverage of psychedelic drugs in the Nexus archive.
- Psychedelic drugs are going mainstream
Psychedelic drugs like mushrooms and LSD are becoming mainstream as commercial success for treatments based on these substances appears more feasible. The article highlights a shift from theoretical potential to practical application in commercial settings.
- The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals growing pharmaceutical industry interest in psychedelic drugs for mental health treatment. The move reflects broader acceptance of this previously stigmatized medication class.
- Eli Lilly makes $3.8 billion bet on psychedelic drugs
Eli Lilly will acquire a psychedelic drug developer for up to $3.8 billion, focusing on AtaiBeckley’s BPL-003 nasal spray in late-stage trials for treatment-resistant depression. Analysts project annual sales of $1-$2 billion if the drug succeeds. The company aims to leverage psychedelic chemicals for psychiatric treatments, though challenges in placebo-controlled trials and past industry scandals remain.
- FDA grants quick review for 3 psychedelic drug trials
The FDA has expedited the review of three experimental psychedelic drugs intended to treat major depression and post-traumatic stress disorder. NBC News' Erika Edwards highlights the FDA's evaluation process for safety and efficacy of these drugs.
- FDA grants quick review for 3 psychedelic drug trials
The FDA has prioritized the review of three psychedelic drugs, a move by the Trump administration to enhance access to these treatments. This action aims to expedite the approval process for potential therapeutic uses of psychedelics.
- Trump admin loosens regulations on state-licensed medical marijuana
The Trump administration reclassified state-licensed medical marijuana from Schedule I to Schedule III, aiming to expand research and patient access. President Trump also signed an executive order to expedite psychedelic drug research, citing potential benefits for veterans with mental health issues.
- Rogan: Trump ‘called me a liberal’ at White House
Podcaster Joe Rogan revealed that President Trump called him a liberal during a White House event focused on advancing psychedelic drug research, including ibogaine. The event, which included an executive order signed by Trump, drew criticism from some attendees, as noted by guest Luis J. Gomez.
- Trump order could fast-track review of psychedelic ibogaine. What is it?
President Trump signed an executive order to expedite the review of psychedelic drugs, including ibogaine. The order aims to fast-track regulatory processes for these substances.
- FDA Commissioner Marty Makary breaks down Trump's executive order on psychedelics
President Trump signed an executive order to expand research into psychedelic drugs for mental health treatment. FDA Commissioner Dr. Marty Makary discusses the implications with CBS News.
- Joe Rogan joins Trump to sign order allowing psychedelic drug research
Podcaster Joe Rogan joined President Donald Trump in the Oval Office to witness the signing of an executive order aimed at accelerating research on psychedelic drugs for treating mental health disorders. The order seeks to provide new treatment options for individuals suffering from debilitating mental health conditions.
- Trump jokes about asking for ibogaine at executive order signing
President Donald J. Trump joked about requesting ibogaine during an executive order signing that directs the FDA to review psychedelic drugs designated as breakthrough therapy. The event highlighted a lighthearted moment amid a serious policy directive.